Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, NY, November 27, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December.
News
Royalty Pharma published press releases by date and/or category
Royalty Pharma Announces Inaugural Prize For Impact In Healthcare
NEW YORK, NY, November 14, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient’s work.
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
NEW YORK, NY, November 7, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO for $125 million in cash upfront.
Royalty Pharma Reports Third Quarter 2024 Results
NEW YORK, NY, November 6, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts.
Royalty Pharma And Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement For Niktimvo
NEW YORK, NY, and WALTHAM, MA, November 4, 2024 - Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Royalty Pharma has entered into a $350 million synthetic royalty funding agreement with Syndax based on U.S. net sales of Niktimvo (axatilimab-csfr).
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
NEW YORK, NY, October 16, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open.
Royalty Pharma Declares Fourth Quarter 2024 Dividend
NEW YORK, NY, October 11, 2024 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share.
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
NEW YORK, NY, and COPENHAGEN, DENMARK, September 3, 2024 - Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath.
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
NEW YORK, NY, August 28, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley’s 22nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET.
Royalty Pharma Reports Second Quarter 2024 Results
NEW YORK, NY, August 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts.
